Table 3.
MiRNAs implicated in SSc.
| miRNAs (chromosome) |
Expression | Cell type/tissue | Target gene | Effect | References |
|---|---|---|---|---|---|
|
miR-29a
(chromosome 7) |
↓ | Fibroblasts Skin Skin of bleomycin-treated mice |
COL1A1
COL3A1 TAB1 |
Antifibrotic | Maurer et al.74 |
| Jafarinejad-Farsangi et al.75 | |||||
| Ciechomska et al.76 | |||||
|
miR-196a
(chromosome 12) |
↓ | Fibroblasts Skin |
COL1A1
COL1A2 |
Antifibrotic | Makino et al.77 |
| Honda et al.78 | |||||
|
miR-let-7d
(chromosome 9) |
↓ | Skin | N.D. | N.D. | Izumiya et al.79 |
|
miR-let-7a
(chromosome 9) |
↓ | Fibroblasts Skin Serum |
COL1A1
COL1A2 |
Antifibrotic | Makino et al.80 |
|
miR-135b
(chromosome 1) |
↓ | Fibroblasts Serum Monocytes |
STAT6 | Antifibrotic | O’Reilly et al.81 |
|
miR-132
(chromosome 17) |
↓ | Fibroblasts | MeCP2 | Antifibrotic | Henderson et al.82 |
|
miR-202-3p
(chromosome 10) |
↑ | Skin | MMP1 | Profibrotic | Zhou et al.84 |
|
miR-155
(chromosome 21) |
↑ | Fibroblasts Skin Serum |
CSNK1A1
SHIP1 |
Profibrotic | Yan et al.85 |
| Dolcino et al.86 | |||||
| Artlett et al.87 | |||||
|
miR-150
(chromosome 19) |
↓ | Fibroblasts | ITGB3 | Antifibrotic | Honda et al.88 |
|
miR-21
(chromosome 17) |
↑ | Fibroblasts Skin Serum SSc serum-treated MVECs |
SMAD7 | Profibrotic Antiapoptotic |
Henry et al.73 |
| Jafarinejad-Farsangi et al.89 | |||||
|
miR-145
(chromosome 5) |
↓ | Fibroblasts Skin SSc serum-treated MVECs |
SMAD3 | Antifibrotic | Henry et al.73 |
| Zhou et al.92 | |||||
|
miR-146b
(chromosome 10) miR-130b (chromosome 22) miR-31 (chromosome 9) miR-34a (chromosome 1) |
↑ | Fibroblasts Skin SSc serum-treated MVECs |
N.D. | N.D. | Zhou et al.92 |
| Lou et al.93 | |||||
|
miR-193b
(chromosome 16) |
↓ | Fibroblasts Skin |
PLAU | Regulation of uPA expression | Iwamoto et al.94 |
|
miR-618
(chromosome 12) |
↑ | pDCs | IRF8 | Inhibition of pDCs differentiation | Rossato et al.95 |
|
miR-5196
(chromosome 19) |
↑ | Monocytes |
TIMP1
FRA2 |
Antifibrotic | Steen et al.97 |
|
miR-17~92
(autosomal) miR-16 (chromosome 13) miR-223 (X chromosome) miR-638 (chromosome 19) |
Differentially expressed between SSc patients and healthy controls | Plasma | N.D. | N.D. | Steen et al.97 |
|
miR-223
(X chromosome) miR-181b (chromosome 1) miR-342 (chromosome 14) miR-184 (chromosome 15) |
Differentially expressed between lcSSc and dcSSc | Plasma | N.D. | N.D. | Wuttge et al.98 |
|
miR-409-3p
(chromosome 14) miR-184 (chromosome 15) miR-92a (X chromosome) miR-29a (chromosome 7) miR-101 (chromosome 1) |
Correlating with the disease autoantibody profiles | Plasma | N.D. | N.D. | Wuttge et al.98 |
|
miR-483-5p
(chromosome 11) |
↑ | Serum | N.D. | Profibrotic | Chouri et al.99 |
|
miR-let-7a-5p
(chromosome 9) miR-26b-5p (chromosome 2) miR-29b-3p (chromosome 7) miR-129-5p (chromosome 7) miR-133a-3p (chromosome 18) miR-140-5p (chromosome 16) miR-145-5p (chromosome 5) miR-146a-5p (chromosome 5) miR-196a-5p (chromosome 12) miR-200a-3p (chromosome 1) miR-223-3p (X chromosome) |
↓ | Serum exosomes | N.D. | Antifibrotic | Chouri et al.99 |
| Wermuth et al.100 | |||||
|
miR-let-7g-5p
(chromosome 3) miR-17-5p (chromosome 13) miR-21-5p (chromosome 17) miR-23b-5p (chromosome 9) miR-29a-3p (chromosome 7) miR-150-5p (chromosome 19) miR-155-5p (chromosome 21) miR-215-5p (chromosome 1) miR-503-5p (X chromosome) |
↑ | Serum exosomes | N.D. | Profibrotic | Chouri et al.99 |
| Wermuth et al.100 | |||||
|
miR-4484
(chromosome 10) |
↑ | Serum | MMP21 | Profibrotic | Rusek et al.102 |
|
miR-92a
(X chromosome) |
↑ | Fibroblasts Serum TGF-β-treated healthy fibroblasts |
MMP1 | Profibrotic | Sing et al.103 |
|
miR-542-3p
(X chromosome) |
↓ | Fibroblasts | BIRC5 | Proapoptotic | Vahidi Manesh et al.104 |
pDC, plasmacytoid dendritic cell: MVEC, microvascular endothelial cell; N.D., not determined; SSc, systemic sclerosis; TGF-β, transforming growth factor beta.